OliX's Innovative Obesity Treatment Candidate, OLX501A

Exciting news has emerged regarding OliX's obesity drug candidate, OLX501A, which has demonstrated exceptional results in trials with obese primates. This treatment has shown a significant 29.2% reduction in visceral fat, outperforming global competitors. This suggests not just weight loss, but a potential for improving body composition with a focus on reducing body fat. OliX is a KOSDAQ-listed bio company leveraging its proprietary RNA interference (RNAi) technology to develop treatments for various conditions, including obesity, hair loss, and ophthalmological diseases.

Clinical Trial with Obese Primates

This study involved a direct comparative trial on obese monkeys. OLX501A and a competing global substance were administered twice at a dosage of 3mg/kg, with a one-month interval between administrations. Various metrics were then evaluated, including target gene suppression rates, changes in visceral fat, and efficacy-related biomarkers.

• Visceral fat reduction in the OLX501A group: 29.2%
• Visceral fat reduction in the competitor group: 10.0%
• Visceral fat change in the control group: 11.1% increase

These results clearly demonstrate that OLX501A is more effective in reducing visceral fat compared to other substances.

Effective Fat Reduction Mechanism

OLX501A aims to promote fat breakdown by suppressing the expression of the ALK7 gene in fat cells. Notably, it holds the potential to reduce body fat without relying on appetite suppression. At 70 days post-administration, the ALK7 target gene suppression rate measured in subcutaneous fat was approximately 90%, comparable to the competitor substance. However, the significant difference in visceral fat reduction indicates that OLX501A more effectively translates target suppression into actual fat breakdown and body composition improvement.

OliX's Future Plans

OliX CEO Lee Dong-ki stated, "OLX501A aims not just for weight loss, but for improving body composition by selectively reducing body fat while preserving muscle mass as much as possible." He added, "We are proceeding with non-clinical development without setbacks, targeting the submission of an Investigational New Drug (IND) application in the first half of 2027." If these plans come to fruition, it could potentially revolutionize the paradigm of obesity treatment.

OliX's OLX501A is gaining attention as a novel drug candidate that could bring about innovative changes in the field of obesity treatment, and future research outcomes are highly anticipated.